SKI V

• UNSPSC Description:

  SKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC50 of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC50 of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity[1][2].

• Target Antigen:

  Apoptosis; PI3K; SphK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Immunology/Inflammation;PI3K/Akt/mTOR

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ski-v.html

• Purity:

  98.95

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C1/C(OC2=CC=CC=C12)=C/C3=CC=C(O)C(O)=C3

• Molecular Weight:

  254.24

• References & Citations:

  [1]French KJ, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63(18):5962-9.|[2]French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318(2):596-603.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  24418-86-8